Apollomics (formerly known as CBT Pharmaceuticals) is a biopharmaceutical company committed to developing medicines targeting the growth and proliferation of cancer cells. Its pipeline is comprised of four development-stage assets, which include an oral agent that specifically targets cancer metastasis, a pre-clinical candidate that targets uncontrolled growth signaling pathways, and two investigational products that restore the body’s immune system to recognize and kill cancer cells.